ex (called Recombinant TCR ligands – RTLs). As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolera